[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

DelveInsight: Market Research Reports

DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:

  • Company’s profile and licensing data;
  • New technology studies;
  • Biologic benchmarking;
  • Treatment modality analysis;
  • Competitive landscape;
  • Product assessment; etc.


This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.

DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.

Publications found: 4,118
Sort by:
Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021 US$ 1,500.00

... chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chemotherapy Induced Nausea and Vomiting The report also ...

February 2021 80 pages
Gallbladder cancer - Pipeline Insight, 2021 US$ 1,500.00

... clients within 48 Hours 'Gallbladder Cancer - Pipeline Insight, 2019' report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Gallbladder Cancer development. The report provides ...

February 2021 60 pages
Yellow Fever- Pipeline Insight, 2021 US$ 1,500.00

... clients within 48 Hours 'Yellow Fever - Pipeline Insight, 2019' report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Yellow Fever development. The report provides ...

February 2021 60 pages
Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021 US$ 1,500.00

... and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The report also ...

February 2021 60 pages
End-Stage Renal Disease - Pipeline Insight, 2021 US$ 1,500.00

... and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for End-Stage Kidney Disease The report also covers ...

February 2021 60 pages
Non-Small-Cell Lung Carcinoma (NSCLC) - Pipeline Insight, 2021 US$ 1,500.00

... and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Non-Small Cell Lung Cancer The report also ...

February 2021 60 pages
Brutons Tyrosine Kinase (Btk) inhibitor– Pipeline Insight, 2021 US$ 2,500.00

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Brutons Tyrosine Kinase (Btk) Inhibitor The report ...

February 2021 60 pages
Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2021 US$ 1,500.00

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glycogen Synthase Kinase 3 (GSK-3) Inhibitor The report ...

February 2021 60 pages
LAG-3 Antagonist - Pipeline Insight, 2021 US$ 2,000.00

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “LAG-3 Antagonist The report assesses the active LAG-3 Antagonist ...

February 2021 70 pages
Lipoxygenase Inhibitors - Pipeline Insight, 2021 US$ 1,500.00

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Lipoxygenase Inhibitor (LOX Inhibitor) The report ...

February 2021 80 pages
Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2021 US$ 1,500.00

... , product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitor The ...

February 2021 60 pages
Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2021 US$ 1,500.00

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Polo-Like Kinase 1 (PLK1 )Inhibitor The report ...

February 2021 60 pages
Atrial Fibrillation - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Atrial Fibrillation - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeli...

February 2021 60 pages
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021,” report provides comprehensi...

February 2021 60 pages
Graves Ophthalmopathy - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Graves Ophthalmopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipe...

February 2021 60 pages
IgA Nephropathy- Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “IgA Nephropathy – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline...

February 2021 60 pages
MALT Lymhoma - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma – Pipeline Insight, 2021,” report provides comprehensive insights ab...

February 2021 60 pages
Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies...

February 2021 60 pages
Postoperative pain - Pipeline Insight, 2021 US$ 2,500.00

This report can be delivered to the clients within 2-3 Business Days DelveInsight’s, “Postoperative pain - Pipeline Insight, 2021,” report provides comprehensive insights about 60+ companies and 60+...

February 2021 200 pages
ACALABRUTINIB - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “ACALABRUTINIB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product...

February 2021 30 pages
Aliqopa - Drug Insight and Market Forecast - 2030 US$ 2,750.00

This report can be delivered to the clients within 48 Hours OVERVIEW “Aliqopa - Drug Insight and Market Forecast - 2030” report by DelveInsight outlays comprehensive insights of the product indicate...

February 2021 30 pages
ARIMOCLOMOL - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “ARIMOCLOMOL - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product fo...

February 2021 30 pages
ATEZOLIZUMAB - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “ATEZOLIZUMAB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product f...

February 2021 30 pages
BI 764524 - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “BI 764524 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for...

February 2021 30 pages
BLINATUMOMAB - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “BLINATUMOMAB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product f...

February 2021 30 pages
BRENTUXIMAB VEDOTIN - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “BRENTUXIMAB VEDOTIN - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational pr...

February 2021 30 pages
DB-102 - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “DB-102 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Dif...

February 2021 30 pages
E-Selectin inhibitor– Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48 hrs DelveInsight’s, “E-Selectin inhibitor– Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 7+ pipeline dr...

February 2021 60 pages
FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48 hrs DelveInsight’s, “FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies a...

February 2021 60 pages
LONCASTUXIMAB TESIRINE - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “LONCASTUXIMAB TESIRINE - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational...

February 2021 30 pages
RG 7774 - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “RG 7774 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Di...

February 2021 30 pages
TREAKISYM - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “TREAKISYM - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for...

February 2021 30 pages
UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigation...

February 2021 30 pages
VENGLUSTAT - Emerging Insight and Market Forecast - 2030 US$ 3,250.00

This report can be delivered to the clients within 48 Hours “VENGLUSTAT - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for...

February 2021 30 pages
Zydelig - Drug Insight and Market Forecast - 2030 US$ 2,750.00

This report can be delivered to the clients within 48 Hours OVERVIEW “Zydelig - Drug Insight and Market Forecast - 2030” report by DelveInsight outlays comprehensive insights of the product indicate...

February 2021 30 pages
Abnormal Glucose tolerance-Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Abnormal Glucose Tolerance – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+...

February 2021 60 pages
Adult-onset growth hormone deficiency - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Adult-onset growth hormone deficiency - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ compa...

February 2021 60 pages
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Pipeline Insight, 2021,” report provides comprehensive in...

February 2021 60 pages
Advanced Non-squamous and squamous NSCLC - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Advanced Non-Squamous & Squamous NSCLC – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ com...

February 2021 60 pages
Advanced Urotheilal carcinoma - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Advanced Urothelial Carcinoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies an...

February 2021 60 pages
Alpha Thalassemia - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Alpha Thalassemia – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline...

February 2021 60 pages
Anti-CD22 therapies - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD22 therapies - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipelin...

February 2021 60 pages
Anti-CD30 therapies - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD30 therapies - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipelin...

February 2021 60 pages
AXL Kinase inhibitor - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48 Hours DelveInsight’s, “AXL Kinase inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeli...

February 2021 60 pages
C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021,” report provides comprehensive insights abo...

February 2021 60 pages
C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 24 Hours DelveInsight’s, “C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ co...

February 2021 60 pages
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021,” report provides comprehensive insights...

February 2021 60 pages
CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ com...

February 2021 60 pages
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “CAR T-Cell Therapy for Non-Hodgkin’s lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about...

February 2021 60 pages
Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021 US$ 1,500.00

This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021,” report provides comprehensive insights about...

February 2021 60 pages

Filters

Search

Categories

10
10
3,115
629
354

Publishers

4,118

Regions

4,118

Price

Date

Pages

Offers